Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ChemoCentryx Inc.

www.chemocentryx.com

Latest From ChemoCentryx Inc.

Vifor Pharma: Targets Acquisitions As Pure-Play Strategy Delivers

Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.

 

Sales & Earnings Companies

ChemoCentryx/Vifor Change Tack On EU Avacopan Filing

ChemoCentryx and Vifor Fresenius have changed their conditional marketing authorization application for avacopan to a full MAA in the EU after it emerged that data from the ADVOCATE study will be more comprehensive than expected.
Approvals Europe

EMA’s PRIME Is Driving Innovation, But Too Early To Tell If Drugs Will Reach Patients Faster

With just three marketing applications filed, the European Medicines Agency says it is too soon to say whether PRIME, its priority medicines scheme, is meeting its objective. The agency is satisfied, though, that the scheme has started to drive innovation.

Market Access Research & Development

Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Musculoskeletal & Connective Tissue Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ChemoCentryx Inc.
  • Senior Management
  • Thomas J Schall, PhD, Pres. & CEO
    Susan M Kanaya, EVP, CFO & Chief Administrative Officer
    Markus J Cappel, PhD, CBO
    William Fairey, EVP, COO
  • Contact Info
  • ChemoCentryx Inc.
    Phone: (650) 210-2900
    850 Maude Ave.
    Mountain View, CA 94043
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register